Company news

Dizal (Jiangsu) Pharmaceutical Co. Ltd. news in 2025

Dizal (Jiangsu) Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors

December 24, 2025

Announcement on the Resignation of Independent Directors

December 18, 2025

Announcement on Changing Registered Capital, Amending the Articles of Association, and Handling Industrial and Commercial Change Registration

December 17, 2025

Announcement on Listing and Circulation of Shares from the 1st Exercise Window of the 2nd Exercise Period under the 2020 Employee Stock Option Plan

December 15, 2025

Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

December 9, 2025

Announcement on Election of Employee Director

November 24, 2025

Announcement on Vesting Results in the 2nd Vesting Period for Category I Incentive Objects of Those Initially Granted in the 2022 Restricted Stock Incentive Plan and Stock Listing

November 10, 2025

Announcement on Voluntary Disclosure of Information Regarding Multiple Studies on Golidocitinib (Gaoruize) and Birelentinib Included in the 67th Annual Meeting of the American Society of Clinical Hematology (ASH)

November 4, 2025

Announcement on Initial Public Offering of Temporarily Idle Raised Funds for Cash Management

October 30, 2025

Announcement on Convening the Q3 2025 Performance Briefing

October 24, 2025

Announcement on Circulation of Restricted Shares Issued to Specific Objects

October 10, 2025

Announcement on Release of Multiple Latest Research Results in the Field of Lung Cancer by the Company at the 2025 World Conference on Lung Cancer (WCLC)

September 9, 2025

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

September 5, 2025

Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors

August 22, 2025

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

August 6, 2025

Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer

July 23, 2025

Announcement on Result of Shareholding Reduction by Senior Management Member

July 8, 2025

Announcement on Cancellation of Partial Special Accounts for Raised Funds

July 4, 2025

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

July 2, 2025

Announcement on Release of Pledge of Partial Shares of Shareholder

June 30, 2025

Announcement on Share Reduction Plan for Senior Management Members

June 25, 2025

Announcement on the Listing and Circulation of Some Restricted Shares in Initial Public Offering

June 23, 2025

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

June 19, 2025

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

June 12, 2025

Notice on Convening the 2024 Annual General Meeting

May 28, 2025

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

May 26, 2025

Voluntary Disclosure Announcement on the Release of the Latest Research Results of DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Conference

May 23, 2025

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

May 15, 2025

Announcement on Result of Share Reduction by Director and Senior Management Member

May 8, 2025

2024 Annual Report

April 29, 2025

Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing

April 25, 2025

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

April 24, 2025

Announcement on Results of Issuing Shares to Specific Objects and Changes in Capital Stock

April 21, 2025

Announcement on Voluntary Disclosure of Golidocitinib's Inclusion in the Level-I Recommendation of the CSCO Guidelines for the Diagnosis and Treatment of Lymphoma (2025 Edition)

April 18, 2025

Announcement on Correction to the Signing of Agreement on Supervision over Deposit in Special Account for Raised Funds

April 16, 2025

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

April 1, 2025

Announcement on Resolution of the 1st Extraordinary General Meeting in 2025

March 25, 2025

Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer

March 20, 2025

Announcement on Documents like Prospectus (Registration Draft) for Issuance of Shares to Specific Objects

March 9, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 24, 2025

Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission

February 7, 2025